Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $32.8100 (3.86%) ($32.8100 - $33.1100) on Mon. Oct. 25, 2010. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.85% (three month average) | RSI | 59 | Latest Price | $32.8100(3.86%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 1.3% a day on average for past five trading days. | Weekly Trend | VBIV advances 1.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(19%) EEM(12%) FXI(12%) IWM(12%) OIH(12%) | Factors Impacting VBIV price | VBIV will decline at least -3.425% in a week (0% probabilities). TLT(-6%) TIP(0%) SHY(1%) LQD(2%) XLU(5%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.425% (StdDev 6.85%) | Hourly BBV | 0 () | Intraday Trend | -0.9% | | | |
|
5 Day Moving Average | $31.07(5.6%) | 10 Day Moving Average | $31.08(5.57%) | 20 Day Moving Average | $30.73(6.77%) | To recent high | -10.2% | To recent low | 82% | Market Cap | $7.568b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |